In this position, Mr Paul will lead educational and informational efforts to support clinicians using the company's proprietary products, including the Caris Target Now molecular profiling and therapeutic guidance test.
These products provide treatment options associated with clinical benefit for cancer patients based on the molecular profile and genetic make-up of the specific tumor, and the Carisome Platform, a proprietary, blood-based technology currently being developed for earlier, more accurate and less invasive testing for cancer and other complex diseases.
Mr Paul will also assume responsibility for the direction of post-market study activity designed to further demonstrate the clinical value and patient care benefits derived from the company's personalized medical services. He will guide these efforts to help clients provide optimal treatment to their patients.
Most recently, Mr Paul served as the head of clinical and scientific affairs for the National Pharmaceutical Council in Washington, District of Columbia. Prior to that role, he led significant medical affairs organizations for both Novartis and AstraZeneca.
Jerry Martino, executive vice president and COO of the company, said: “Caris is aware that game-changing technologies, like those we provide, will create education challenges in the healthcare marketplace.
“Training and other educational opportunities, as well as ongoing communication and collaboration with the clients using these new technologies, will be critical not only to the success of our products, but to the improvement of patient care.”
Will Mr Paul's experience benefit the company?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.